Key Points
- Pfizer boosted its full-year guidance for both revenue and earnings.
- Its oncology segment saw significant growth, driven by the recent acquisition of Seagen.
- COVID-19 vaccine sales declined sharply.
Pfizer (PFE -0.21%), a global pharmaceutical giant, delivered its second-quarter results on July 30, reporting revenue of $13.3 billion and adjusted diluted earnings per share (EPS) of $0.60. The quarter was mixed, with bright spots in oncology growth and product pipeline advancements being offset by declines in COVID-19 vaccine revenues. But the company raised its full-year revenue and earnings guidance.
| Metric | Q2 2024 | Q2 2023 | % Change |
|---|---|---|---|
| Revenue | $13.3 billion | $13 billion | 2% |
| Adjusted net income | $3.4 billion | $3.8 billion | (11%) |
| Adjusted diluted EPS | $0.60 | $0.67 | (11%) |
| Comirnaty revenue | $195 million | $1.49 billion | (87%) |
| Paxlovid revenue | $251 million | $143 million | 76% |
| Legacy Seagen revenue | $845 million | NA | NA |
| Global biopharma revenue | $13 billion | $12.7 billion | 2% |
| Eliquis revenue | 1.9 billion | $1.8 billion | 7% |
| Ibrance revenue | $1.1 billion | $1.2 billion | (9%) |
Company Overview
New York-based Pfizer focuses on developing medications and vaccines, and its Q2 results underscored its significant investments in oncological advancements and its robust R&D pipeline.
Recently, Pfizer bolstered its product pipeline and catalog with the strategic acquisition of cancer specialist Seagen. In Q2, R&D spending increased operationally by 2% to $2.7 billion. The oncology segment grew by 26% year over year, largely due to newly approved products and strong performances from medicines acquired in the Seagen deal.
Notable Developments During Q2 2024
Revenue for Q2 2024 was $13.3 billion, compared to $13.0 billion in Q2 2023.
Revenues from Comirnaty, Pfizer's COVID-19 vaccine, experienced an 87% operational decline to $195 million. Conversely, revenues from Paxlovid, Pfizer's COVID-19 antiviral treatment, increased by 79% to $251 million. These changes reflect the shifting landscape of the pandemic and the demand for associated treatments.
The oncology segment grew significantly. Padcev and Adcetris, both acquired from Seagen, generated revenues of $394 million and $279 million, respectively. Original Pfizer product Ibrance saw a 9% global revenue decline despite regional successes.
Pfizer also focused on product diversification. It divested its early-stage gene therapy portfolio to Alexion in the quarter, but it continues to invest in a diverse range of therapeutic areas. Notably, global biopharma revenue rose slightly by 2% year over year.
On the pricing strategy front, the upcoming Medicare price negotiations for Eliquis will be crucial. This process begins in 2026 and will likely impact future pricing structures. Pfizer also announced an ambitious cost-cutting plan, projecting $1.5 billion in savings through its manufacturing optimization program by the end of 2027.
Collaborations remained a pivotal strategy. Partnerships with BioNTech to develop further COVID-19 therapeutics and vaccines continued. Capital allocation for business development amounted to $200 million, while $5.2 billion was invested in internal R&D projects.
Looking Ahead
Management revised its 2024 financial guidance, reflecting optimism about Pfizer's product pipeline and strategic initiatives. Full-year revenue guidance was raised to the $59.5 billion to $62.5 billion range, up from a range of $58.5 billion to $61.5 billion previously. Adjusted EPS expectations were raised to a range of $2.45 to $2.65, up from $2.15 to $2.35 previously.
For investors, monitoring how Pfizer navigates the ongoing decline in COVID-19 product revenues will be key. The company's ability to leverage its robust oncology portfolio, expand market reach, and optimize costs will be crucial for sustained growth in upcoming quarters.
